WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted
anticancer therapeutics, today announced that the Company will host a
conference call at 8:00 a.m. ET on Friday, April 26, 2013, to discuss
ImmunoGen's financial results for the three-month period ended March 31,
2013 — the third quarter of the Company's 2013 fiscal year.
To access the live call by phone, dial 913-312-0843. Passcode: 4566767.
The call also may be accessed through the Investor Information section
of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through May 10, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
Targeted Antibody Payload (TAP) technology uses a tumor-targeting
monoclonal antibody to deliver one of ImmunoGen's highly potent
cancer-cell killing agents specifically to tumor cells. Ten TAP
compounds are now in the clinic, of which three are wholly owned by the
Company. The most advanced compound using ImmunoGen's TAP technology,
KADCYLA (formerly T-DM1), has been approved for marketing in the US and
is undergoing regulatory review in Europe and Japan; it is being
commercialized in the US by Genentech, a member of the Roche Group. More
information about ImmunoGen can be found at www.immunogen.com.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive
Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For
Media:
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media